Enthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company…

MILAN--(BUSINESS WIRE)--Enthera Pharmaceuticals (Enthera), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board.

Kazumi brings experience as both an entrepreneur and an investor within the field of biotechnology. She is currently the CEO of Twentyeight-Seven, a biotech company focused on novel RNA biology that she co-founded alongside prominent Harvard investigators. Kazumi was also a co-founder and CEO of Mitobridge, a start-up company developing mitochondrial drugs for the treatment of muscle and kidney diseases, until its acquisition by Astellas Pharma in 2018. Prior to Mitobridge, she was a co-founder and start-up CEO of Epizyme (NASDAQ:EPZM), a leader in novel epigenetic therapeutics for cancer. She has also been a Managing Director at MPM Capital.

Lisa is a senior pharmaceutical executive with more than 20 years of experience in research and drug discovery. She is currently Chief Scientific Officer and Head of Research at Magenta Therapeutics, where she provides strategic direction, oversight and execution for research and discovery efforts. Lisa joined Magenta after 15 years in leadership positions at the AbbVie Bioresearch Center, most recently as Vice President, Immunology Discovery and Site Head, where she was responsible for all immunology discovery scientific and portfolio decisions. Prior to AbbVie, Lisa served as a Research Fellow and Group Leader in Inflammation & Immunology at Pfizer.

Kazumi and Lisa will work closely with the leadership team and other Board and Scientific Advisors to support the growth and development of Enthera.

Giovanni Amabile, CEO of Enthera, commented: The appointment of Kazumi Shiosaki and Lisa Olson will greatly benefit Enthera. Kazumi is a biotech veteran with an outstanding track record in corporate development and fundraising across both European and US markets, while Lisa brings extensive experience in drug discovery and development from roles at Magenta Therapeutics, AbbVie and Pfizer. The support of Kazumi and Lisa will be instrumental as we progress our pipeline and take Enthera to the next level.

Kazumi Shioshaki, newly appointed Board member of Enthera, stated: Enthera Pharmaceuticals is an exciting young biotech, with an innovative and unique approach to treating underserved autoimmune disorders. The recent Series A financing round was a great achievement, and I look forward to working with the Enthera team as we push onwards and use these funds to build a world-class international company with first-in-class therapeutics.

Lisa Olson, newly appointed Scientific Advisory Board member, added: I look forward to supporting Giovanni and the rest of the Enthera team in the progression of their clinical assets. The Companys lead product is a promising biologic candidate for type 1 diabetes and gastrointestinal diseases, with the wider pipeline offering potential treatments for several underserved autoimmune conditions.

Enthera recently closed a EUR 28 million funding, with investment from renowned investors Sofinnova Partners, AbbVie and JDRF T1D Fund. The funds will be used to accelerate the Companys lead program, Ent001, to clinical proof-of-concept.

Kazumi started her career at AbbVie (then Abbott Labs) and from there joined Millennium (now part of Takeda), where she worked in senior functions in both research and corporate development. She is also a Board member of the Sandford Burnham Prebys Institute. Kazumi holds a PhD in Synthetic Chemistry from UC Berkeley.

Lisa began her career as Assistant Professor at Washington University School of Medicine, following a post-doctoral cardiovascular fellowship at the University of Chicago. She holds a PhD from the University of Illinois at Urbana-Champaign, and a Bachelor of Science from Iowa State University.

ENDS

High-resolution photos of Kazumi Shiosaki and Lisa Olson are available upon request.

Notes to Editors

About Enthera

Enthera Srl is a biotech company developing first-in-class biologics to transform the treatment paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way. The Companys primary target indications are type 1 diabetes (T1D) and inflammatory bowel disease (IBD).

Enthera's pioneering approach capitalizes on the key discovery of the IGFBP3/TMEM219 pathway, which is involved in beta cell and stem cell apoptosis in pancreas and gut, respectively.

The Company is building a pipeline of inhibitory monoclonal antibodies (mAbs) and fusion proteins targeting the pathway via multiple angles. Its lead program Ent001 is the only drug in development with the potential to restore the endogenous pancreatic stem cell compartment in T1D as well as the original intestine structure in IBD, in order to re-stablish organ function.

Enthera is a private company headquartered in Milan, Italy and founded in 2016 by Prof Paolo Fiorina and Dr Francesca DAddio at BiovelocITA, an Italian biotech accelerator. The Company is backed by Sofinnova Partners and JDRF T1D fund. Entheras discovery engine and assets are protected by a broad portfolio of patents.

For more information, visit https://www.entherapharmaceuticals.com/

Connect with us on LinkedIn.

Read the rest here:
Enthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company...

Meat-Tech Agrees to Acquire Cultured Fat Pioneer ‘Peace of Meat’ – PRNewswire

NESSZIONA,Israel, Dec. 8, 2020 /PRNewswire/ -- Meat-Tech 3D Ltd. (TASE: MEAT), today announced that it has signed an agreement to acquire 100% of the share capital of Peace of Meat PV, a pioneering Belgian producer of cultured avian products, for EUR 15 million in a combination of cash and Meat-Tech ordinary shares. The Company believes that it will be able to leverage Peace of Meat's technologies, including through novel hybrid food products, to expedite market entry while Meat-Tech develops an industrial process for cultivating and producing real meat using 3D bioprinting technology, without harming animals. The acquisition is expected to close in the coming weeks, subject to customary closing conditions.

Peace of Meat has developed a proprietary, stem-cell-based bioreactor technology for cultivating animal fats from chicken and ducks, without harming animals. It has conducted a number of taste tests, demonstrating the potential that its cultured fat has to enhance the taste of plant-based protein products. The technology's first expected application is in hybrid food products, combining plant-based protein with cultured animal fat, designed to provide meat analogues with qualities of "meatiness" (taste and texture) closer to that of conventional meat products. Meat-Tech estimates that the first hybrid products based on Peace of Meat technology could hit the market as early as 2022.

Pursuant to the acquisition agreement, Meat-Tech will pay half of the consideration immediately, with the payment of the balance subject to Peace of Meat complying with preset technological milestones over a period of two years, that were designed to scale up cultured fat production capabilities in preparation for market entry. To that end, it was agreed that Peace of Meat's management will continue in place to lead the development process.

This acquisition is consistent with Meat-Tech's growth strategy, aiming to streamline development processes and expand the Company's product range to penetrate cultured meat technology markets as quickly as possible. Meat-Tech is working to create synergy and added value for food manufacturers in the advanced production of cultured meat, while sustaining animal welfare and meeting the growing global demand for meat.

Sharon Fima, Meat-Tech's CEO: "Meat-Tech's novel technology for producing meat using 3D printing is gaining increasing international recognition. Boosted by our acquisition strategy, we believe we can turn Meat-Tech into a leading global center and home for innovative and groundbreaking cell-based food solutions that are both healthy and environmentally friendly. The combination of Peace of Meat's human capital and technology make this acquisition a significant step in that direction. I am pleased that both management teams share a common vision and strategy, and can join forces to advance the development of cultured food products with the potential to create real alternatives in the global meat market."

David Brandes and Dirk von Heinrichshorst, Co-Founders of Peace of Meat:"In an industry that is working towards a kinder, more sustainable planet, joining forces makes us stronger together. Peace of Meat has developed a powerful system for upscaled cultured biomass production and together with Meat-Tech we intend to accelerate product development toward commercialization.

"While Peace of Meat's core activity remains focused on the production of tasty, cultured fat as a B2B ingredient for meat alternatives, we see tremendous opportunity in jointly building a leading food-tech enterprise with Meat-Tech, based on a cellular platform.

"As entrepreneurs, we are excited about this acquisition as it poses a novel way of building and growing a company while significantly increasing the prospects of launching our product into the market."

About Peace of Meat:

Peace of Meat was established in Belgium in 2019 and is developing cultured chicken fat directly from animal cells without the need to grow or kill animals. The company believes that its innovative technology has the potential to support an industrial process for the production of cultured chicken fat. Peace Of Meat has entered into a number of scientific and commercial collaborations, in the process of positioning itself as a future B2B provider, with the potential to cover the entire value chain and to accelerate research and production processes in the industry, and has conducted taste tests for hybrid products it has developed.

About Meat-Tech:

Meat-Tech is developing a novel biological printing process designed to create living, edible meat tissue using cellular agriculture. Meat-Tech is developing technologies, processes and machines for cultivating, producing, and printing cultured meat. The company believes that it was the first in the world to use edible biological inks to 3D-print living tissue made up of various cells of bovine origin. The Company has the technology, knowledge and experience in applying tissue engineering practices for producing fat and muscle tissue for food consumption, as well as the ability to print, using a 3D bioprinter, a combination of live animal cells, growth factors and biological materials to produce living tissues that mimic the characteristics of natural tissue.

Forward-Looking Statements:

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company's development of the next generation of cultured meat food products by leveraging 3D digital printing technology, Peace of Meat's development of cultured fat products, the expected closing of the Company's acquisition of Peace of Meat and the expected post-closing synergies of the combined companies. These forward-looking statements include information about possible or assumed future results of the Company's business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management's current expectation and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Actual results could differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements.

COMPANY / INVESTOR CONTACT:Eran Gabay, Partner, Director of Strategy Gelbart-Kahana Investor Relations: [emailprotected]

SOURCE Meat-Tech 3D Ltd.

Read the rest here:
Meat-Tech Agrees to Acquire Cultured Fat Pioneer 'Peace of Meat' - PRNewswire

Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH -…

NEW YORK, Dec. 8, 2020 /PRNewswire/ --Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that first-in-human data from the first dose cohort of the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial in patients with relapsed or refractory Acute Myeloid Leukemia (AML) were presented at the 62nd American Society of Hematology (ASH) annual meeting. The poster presentation highlighted results from the first three patients treated with the initial subtherapeutic dose level of 0.5 Ci/kg of Actimab-A and venetoclax.

The enrolled patients had a median of 2 prior therapies (range 2-3) and a median bone marrow blast percentage of 30% (range 20 - >60). All 3 patients had poor risk disease with adverse cytogenetics, and each patient had an additional high-risk marker (FLT3-ITD+, antecedent JAK2+ myelofibrosis, or TP53 mutation). One patient who had multiple genetic mutations including IDH2, RUNX1, TP53 and others, achieved a complete remission with incomplete blood count recovery (CRi) after the first cycle of Actimab-A and venetoclax. Next generation sequencing at the end of the first cycle showed that patient was negative for the known IDH2 and RUNX1 mutations. This patient has continued treatment receiving the second cycle and their bone marrow remains normocellular with no excess blasts. In addition, another patient achieved a partial response after one cycle of Actimab-A and venetoclax. There were no Actimab-A related dose limiting toxicities or nonhematologic Grade 3 or greater related AEs reported in the first cohort. The trial has advanced to the second dose cohort of 1.0 Ci/kg of Actimab-A and venetoclax with patient enrollment ongoing.

Sandesh Seth, Actinium's Chairman and Chief Executive Officer, commented, "This ASH meeting, we are excited to highlight the promising data emerging from both our combination trials with Actimab-A in the R/R AML setting, namely the Actimab-A venetoclax and Actimab-A CLAG-M trials. Particularly compelling is the complete response reported in a patient with complex mutations like TP53 with Actimab-A and venetoclax and the high MRD negativity rate with Actimab-A and CLAG-M. The results clearly demonstrate that a superior clinical effect without adding meaningful toxicity is achievable using Ac-225 ARC's to precisely deliver powerful internal radiation and elicit a potentiating and synergistic treatment effect with chemotherapy and targeted agents. With this clinical validation in hand, we look forward to expanding our ARC combinations with other therapeutic modalities in AML and into additional indications to further establish our leadership position in the field by leveraging our enhanced R&D capabilities including new research facilities and key hires."

Dr. Mark Berger, Actinium's Chief Medical Officer, said, "We were thrilled to report a complete response in the Actimab-A venetoclax combination trial, in addition to the partial response previously highlighted in the abstract. Both responses occurred after just one cycle of a subtherapeutic dose of Actimab-A. These initial results, the one complete response and safety profile to date, support the potential mechanistic synergy of Actimab-A with venetoclax. As a single agent, venetoclax has produced low response rates of 19% in patients with R/R AML1 so we are pleased with the results seen in our first dose cohort. In addition, the clinical data from Actimab-A and Iomab-B presented at this year's ASH demonstrates our strong commitment to addressing the unmet needs of patients with R/R AML with our ARCs as best in class therapeutics, bridge to transplant and targeted conditioning for potentially curable bone marrow transplant. With this in mind, we look forward to guidance on Iomab-B expected from the ad-hoc DMC meeting before year-end."

This Phase 1/2 trial is a multicenter, open label trial of Actimab-A (lintuzumab-Ac225) added to venetoclax for patients with CD33 positive R/R AML. A Phase 2 trial studying Actimab-A as a single agent produced a 69% overall response rate in older unfit patients with newly diagnosed AML.In a poster presentation at the American Association of Cancer Research (AACR) Annual Meeting 2019, Actimab-A was shown to be synergistic with venetoclax in venetoclax resistant cell lines, by depleting MCL-1, a protein shown to mediate resistance to venetoclax. Further, the induction of direct AML cell death via double-stranded DNA breaks by Actimab-A provides a second mechanism for enhancing synergistic potency with venetoclax. Venetoclax is a B-Cell Lymphoma 2 (BCL-2) inhibitor that is jointly developed and marketed by AbbVie and Genentech and is approved for patients with AML, Chronic Lymphocytic Leukemia (CLL), and Small Lymphocytic Leukemia (SLL). Despite its approval in AML, venetoclax has produced low response rates of 19% as a single agent in R/R AML.1 This is due in part to the type of AML, risk factors, and cytogenetics of this patient population. The Phase 2 trial results, together with a synergistic mechanism of action with venetoclax demonstrated in pre-clinical studies, are driving this combination trial with an initial focus on the high unmet needs of R/R patients including those who have relapsed or do not respond to treatment with venetoclax based regimens.

1 Aldosset al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica2018.1888094.

About Actinium's CD33 Program

Actinium's CD33 program is evaluating the clinical utility of Actimab-A, an ARC comprised of the anti-CD33 mAb lintuzumab linked to the potent alpha-emitting radioisotope Actinium-225 or Ac-225. CD33 is expressed in the majority of patients with AML and myelodysplastic syndrome, or MDS, as well as patients with multiple myeloma. The CD33 development program is driven by data from over one hundred treated patients, including a Phase 1/2 trial where Actimab-A produced a remission rate as high as 69% as a single agent. This clinical data is shaping a two-pronged approach for the CD33 program, where at low doses the Company is exploring its use for therapeutic purposes in combination with other modalities and at high doses for use for targeted conditioning prior to bone marrow transplant. Actinium currently has multiple clinical trials ongoing including the Phase 1 Actimab-A CLAG-M and Phase 1/2 Actimab-A venetoclax combination trials and is exploring additional CD33 ARC combinations with other therapeutic modalities such as chemotherapy, targeted agents or immunotherapy.

About Actinium Pharmaceuticals, Inc. (NYSE: ATNM)

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Our lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SIERRA trial is over seventy-five percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings. More information on this Phase 3 clinical trial can be found at http://www.sierratrial.com. I-131 apamistamab will also be studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell therapy and in a Phase 1/2 anti-HIV stem cell gene therapy with UC Davis. In addition, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Ongoing combination trials include our CD33 ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax. Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform. This is where our intellectual property portfolio of over 130 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes. Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc. Website: https://www.actiniumpharma.com/

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Contacts:

Investors: Clayton Robertson Actinium Pharmaceuticals, Inc. [emailprotected]

Hans Vitzthum LifeSci Advisors, LLC [emailprotected](617) 430-9758

SOURCE Actinium Pharmaceuticals, Inc.

http://www.actiniumpharma.com/

Excerpt from:
Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH -...

How do you donate stem cells? Donating cells can help treat cancer, blindness and other conditions – heres how – The Scotsman

Health A new stem cell treatment could restore eyesight in some people

Friday, 4th December 2020, 3:18 pm

Researchers discovered that the cells of damaged retinas could be repaired by injecting genetically modified stem cells into the eye.

The news comes as comedian Al Murray pushed for stem cell donors to come forward, ahead of a charity gig for blood cancer organisation DKMS.

Heres everything you need to know about the scientific discovery - and how you can donate your own stem cells to save the lives of people with blood cell diseases.

Stem cells are produced by bone marrow, and they have the ability to grow into different types of blood cells such as red and white blood cells and platelets.

A stem cell or bone marrow transplant replaces damaged blood cells with healthy ones and can be used to treat conditions affecting the blood cells, like leukaemia and lymphoma.

The transplant involves destroying the unhealthy blood cells and replacing them with the stem cells removed from the blood or bone marrow.

Often, stem cells are taken from one person - usually a close family member or a match with the same or similar tissue type - and they are transferred to the person that needs them.

How could they be used to treat vision damage?

Researchers in Barcelona recently discovered that modified stem cells could potentially help to cure problems with vision.

They found that the cells of damaged eye retinas send out a rescue signal to attract the stem cells that can repair damage.

Stem cells were genetically engineered to make them more sensitive to those signals.

The modified stem cells were transplanted back into mice and human tissue samples and the researchers found that they flocked to the retina cells in large numbers.

In turn, that kept the tissue of the retina alive and functioning.

The new technique is a breakthrough in stem cell research as it suggests stem cells could help to improve sight, and potentially could cure blindness in the future.

Retinal damage is currently incurable and can cause visual disabilities and blindness, especially in older people.

How can stem cells treat conditions?

Stem cells can already be used to treat a number of conditions where the bone marrow is damaged and unable to produce its own healthy blood cells.

Transplants can be used to treat people suffering from different forms of cancer, with someone elses tem cells replacing the patients blood cells that are damaged or destroyed.

Conditions that stem cell transplants can treat include leukemia and lymphoma, which are cancers affecting white blood cells, myeloma, which affects plasma cells, severe aplastic anaemia (bone marrow failure), and other blood disorders.

A stem cell transplant will usually only be carried out if other treatments have been exhausted, but it could save someones life.

How can I donate stem cells?

When its not possible to use someones own stem cells to treat their condition, they need to come from a donor.

However, to improve the chances of the transplant being successful, the donated cells need to have a very similar genetic marker to the patients.

As the number of donors has recently decreased, charities are urgently encouraging healthy people to donate stem cells.

You are able to register to be a donor on the NHS Blood and Transplant website.

The Anthony Nolan charity also takes sign ups, and is specifically looking for younger donors between age 16 and 30.

You will be asked to fill out an application form and will be sent a swab pack so you can be added to the register.

If you ever come up as a match for a patient, you will be contacted by the charity.

Even if you cant join the register, you can donate to Anthony Nolan to help to grow the stem cell register.

Go here to read the rest:
How do you donate stem cells? Donating cells can help treat cancer, blindness and other conditions - heres how - The Scotsman

Worldwide Stem Cell Therapy Market Insights to 2025 – Analysis and Forecasts – GlobeNewswire

December 03, 2020 06:48 ET | Source: Research and Markets

Dublin, Dec. 03, 2020 (GLOBE NEWSWIRE) -- The "Stem Cell Therapy Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Product Type" report has been added to ResearchAndMarkets.com's offering.

This report describes the global market size of Stem Cell Therapy from 2015 to 2019 and its CAGR from 2015 to 2019, and also forecasts its market size to the end of 2025 and its CAGR from 2020 to 2025.

For the geography segment, regional supply, demand, major players, price is presented from 2015 to 2025.

This report covers the following regions:

The key countries for each region are also included such as the United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.

For the competitor segment, the report includes global key players of Stem Cell Therapy as well as some small players.

The information for each competitor includes:

Types Segment:

Key Topics Covered:

Chapter 1 Executive Summary

Chapter 2 Abbreviation and Acronyms

Chapter 3 Preface 3.1 Research Scope 3.2 Research Sources 3.2.1 Data Sources 3.2.2 Assumptions 3.3 Research Method

Chapter 4 Market Landscape 4.1 Market Overview 4.2 Classification/Types 4.3 Application/End-users

Chapter 5 Market Trend Analysis 5.1 Introduction 5.2 Drivers 5.3 Restraints 5.4 Opportunities 5.5 Threats

Chapter 6 Industry Chain Analysis 6.1 Upstream/Suppliers Analysis 6.2 Stem Cell Therapy Analysis 6.2.1 Technology Analysis 6.2.2 Cost Analysis 6.2.3 Market Channel Analysis 6.3 Downstream Buyers/End-users

Chapter 7 Latest Market Dynamics 7.1 Latest News 7.2 Merger and Acquisition 7.3 Planned/Future Project 7.4 Policy Dynamics

Chapter 8 Trading Analysis 8.1 Export of Stem Cell Therapy by Region 8.2 Import of Stem Cell Therapy by Region 8.3 Balance of Trade

Chapter 9 Historical and Forecast Stem Cell Therapy Market in North America (2015-2025) 9.1 Stem Cell Therapy Market Size 9.2 Stem Cell Therapy Demand by End Use 9.3 Competition by Players/Suppliers 9.4 Type Segmentation and Price 9.5 Key Countries Analysis 9.5.1 US 9.5.2 Canada 9.5.3 Mexico

Chapter 10 Historical and Forecast Stem Cell Therapy Market in South America (2015-2025) 10.1 Stem Cell Therapy Market Size 10.2 Stem Cell Therapy Demand by End Use 10.3 Competition by Players/Suppliers 10.4 Type Segmentation and Price 10.5 Key Countries Analysis 10.5.1 Brazil 10.5.2 Argentina 10.5.3 Chile 10.5.4 Peru

Chapter 11 Historical and Forecast Stem Cell Therapy Market in Asia & Pacific (2015-2025) 11.1 Stem Cell Therapy Market Size 11.2 Stem Cell Therapy Demand by End Use 11.3 Competition by Players/Suppliers 11.4 Type Segmentation and Price 11.5 Key Countries Analysis 11.5.1 China 11.5.2 India 11.5.3 Japan 11.5.4 South Korea 11.5.5 Asean 11.5.6 Australia

Chapter 12 Historical and Forecast Stem Cell Therapy Market in Europe (2015-2025) 12.1 Stem Cell Therapy Market Size 12.2 Stem Cell Therapy Demand by End Use 12.3 Competition by Players/Suppliers 12.4 Type Segmentation and Price 12.5 Key Countries Analysis 12.5.1 Germany 12.5.2 France 12.5.3 UK 12.5.4 Italy 12.5.5 Spain 12.5.6 Belgium 12.5.7 Netherlands 12.5.8 Austria 12.5.9 Poland 12.5.10 Russia

Chapter 13 Historical and Forecast Stem Cell Therapy Market in MEA (2015-2025) 13.1 Stem Cell Therapy Market Size 13.2 Stem Cell Therapy Demand by End Use 13.3 Competition by Players/Suppliers 13.4 Type Segmentation and Price 13.5 Key Countries Analysis 13.5.1 Egypt 13.5.2 Israel 13.5.3 South Africa 13.5.4 Gcc 13.5.5 Turkey

Chapter 14 Summary for Global Stem Cell Therapy Market (2015-2020) 14.1 Stem Cell Therapy Market Size 14.2 Stem Cell Therapy Demand by End Use 14.3 Competition by Players/Suppliers 14.4 Type Segmentation and Price

Chapter 15 Global Stem Cell Therapy Market Forecast (2020-2025) 15.1 Stem Cell Therapy Market Size Forecast 15.2 Stem Cell Therapy Demand Forecast 15.3 Competition by Players/Suppliers 15.4 Type Segmentation and Price Forecast

Chapter 16 Analysis of Global Key Vendors 16.1 Biotime 16.1.1 Company Profile 16.1.2 Main Business and Stem Cell Therapy Information 16.1.3 SWOT Analysis of Biotime 16.1.4 Biotime stem Cell Therapy sales, Revenue, Price and Gross Margin (2015-2020) 16.2 Sanbio 16.3 Bluerock Therapeutics 16.4 Reneuron 16.5 International Stem Cell Corp

For more information about this report visit https://www.researchandmarkets.com/r/71s9qh

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the original post here:
Worldwide Stem Cell Therapy Market Insights to 2025 - Analysis and Forecasts - GlobeNewswire

Gene therapy gives man with sickle cell disease the chance for a better future – UCLA Newsroom

For Evie Junior, living with sickle cell disease has been like running a marathon.

But its a marathon where as you keep going, the trail gets rockier and then you lose your shoes, the 27-year-old said. It gets harder as you get older. Things start to fail and all you can think about is how much worse its going to get down the road.

In sickle cell disease, a genetic mutation causes the blood-forming stem cells which give rise to all blood and immune cells to produce hard, sickle-shaped red blood cells.These misshapen cells die early, leaving an insufficient number of red blood cells to carry oxygen throughout the body. Because of their sickle shape, these cells also get stuck in blood vessels, blocking blood flow and resulting in excruciating bouts of pain that come on with no warning and can leave patients hospitalized for days.

The disease affects 100,000 people in the United States and millions around the world, the majority of whom are of African or Hispanic descent. It can ultimatelylead to strokes, organ damage and early death.

As a child growing up in the Bronx, New York, Junior had to have his gall bladder and spleen removed due to complications from the disease, but he refused to let his condition limit him. He played football, basketball and baseball during the day, even though on some nights he experienced pain crises so severe he couldnt walk.

It was just really routine if I had a sickle cell crisis, he said. Going to the emergency room, staying in the hospital, coming out in a few days and then getting back to normal life.

I want to create a better future

When he was 24 and living in Portland, Oregon, Junior began working as an emergency medical technician. He adopted the same mentality trying to treat his pain episodes the best he could, and hoping they would resolve overnight so he could get back to work. Around that time, though, the crises became harder to manage. He developed pericarditis, an inflammation in the layers of tissue around his heart, and needed six weeks to recover.

The big worry with sickle cell disease is that youre going to die young from some type of complications or damage to your organs, he said. In the last couple of years, Ive been seeing that slowly happen to me and I can only suspect that its going to keep getting worse. I want to create a better future for myself.

In July 2019, in pursuit of that future, Junior enrolled in a clinical trial foran experimental stem cell gene therapy for sickle cell disease. The study is led byUCLA Broad Stem Cell Research Centerphysician-scientistsDr. Donald KohnandDr. Gary Schillerand funded by the California Institute for Regenerative Medicine.

The therapy, developed by Kohn over the past 10 years, is intended to correct the mutation in patients blood-forming stem cells to allow them to produce healthy red blood cells.Kohn has already applied the same concept to successfully treat several immune system deficiencies, includinga cure for a form of severe combined immune deficiency, also known as bubble baby disease.

But sickle cell disease has proven more difficult to treat with gene therapy than those other conditions. Junior volunteered for the trial knowing there was a chance the therapy wouldnt cure him.

Even if it doesnt work for me, Im hoping that it can be a cure later down the road for millions of people, he said.

In July 2020, Junior received an infusion of his own blood-forming stem cells that had been genetically modified to overcome the mutation that causes his disease.

The goal of this treatment is to give him a future, let him plan for college, family or whatever he wants without worrying about getting hospitalized because of another pain crisis, said Kohn,a distinguished professor of microbiology, immunology and molecular genetics, pediatrics, and molecular and medical pharmacology at theDavid Geffen School of Medicine at UCLA.

Reason for optimism

Three months after his treatment, blood tests indicated that 70% of Juniors blood stem cells had the new corrected gene. Kohn and Schiller estimate that even a 20% correction would be enough to prevent future sickle cell complications. Junior said he hasnt had a pain crisis since undergoing the treatment and he has more energy and feels out of breath less often.

I noticed a big difference in my cardiovascular endurance in general even going for a light jog with my dogs, I could feel it, he said.

Junior and his doctors are cautiously optimistic about the results.

Its too early to declare victory, but its looking quite promising at this point, Kohn said. Once were at six months to a year, if it looks like it does now, Ill feel very comfortable that hes likely to have a permanent benefit.

After a lifetime of dealing with the unwelcome surprises of the disease, Junior is even more cautious than his doctors. But as the weeks pass, hes slowly allowing a glimmer of hope that he could soon be someone who used to have sickle cell disease. For him, that hope feels like a burst of happiness thats followed by thoughts of all the things he could do with a healthy future: pursue his dream of becoming a firefighter, get married and start a family.

I want to be present in my kids lives, so Ive always said Im not going to have kids unless I can get this cured, he said. But if this works, it means I could start a family one day.

Continued here:
Gene therapy gives man with sickle cell disease the chance for a better future - UCLA Newsroom

Gene-Editing Therapy CTX001 Reports Durable Effects for TDT, Sickle Cell Patients – MD Magazine

New case data from an ongoing series of clinical trials show investigational CRISPR/Cas9-based gene-editing therapy CTX001 is associated with transfusion independence in patients with transfusion-dependent beta thalassemia (TDT), as well as an absence of vaso-occlusive crises (VOCs) in patients with sickle cell disease.

The findings from the phase 1/2 CLIMB-111 and CLIMB-121 trials, presented at the American Society of Hematology (ASH) 2020 Annual Meeting this weekend, indicate the gene-editing therapy from CRISPR Therapeutics and Vertex Pharmaceuticals may be the best candidate yet for potential curative effects on TDT and sickle cell disease.

About the Therapy

CTX001 is an autologous, ex vivo CRISPR/Cas9 gene-edited therapy being assessed in patients with either TDT or sickle cell disease. It has been granted a litany of promising designations from the US Food and Drug Administration (FDA) for its potentially marketed use, including Fast Track, Orphan Drug, and Rare Pediatric Disease designations.

The gene-editing therapy edits patients hematopoietic stem cells to produce higher levels of fetal hemoglobin (HbF) in red blood cells, potentially reducing the need for TDT transfusions, and the risk of VOCs in sickle cell disease patients.

CLIMB-111 Trial

The ongoing phase 1/2 open-label trial is assessing the efficacy and safety of single-dose CTX001 in patients aged 12-35 with TDT.

In data presented at ASH 2020, 13 patients with TDT had been treated with CTX001, including 8 patients since investigators latest update in June of this year. Seven patients had reached 3 months follow-up after CTX001 infusion, and were included in the initial safety and efficacy analyses.

All 7 patients were transfusion independent at a post-treatment range of 3-18 months. Hemoglobin counts ranged from 9.7-14.1 g/dL, and HbF ranged from 40.9-97.7%.

The safety profiles of observed patients were additionally consistent, with 4 serious adverse events reported in possible relation to CTX001 in 1 patient: headache, hemophagocytic lymphohistiocytosis (HLH), acute respiratory distress syndrome, and idiopathic pneumonia syndrome.

CLIMB-121 Trial

The ongoing phase 1/2 assessment of CTX001 in patients with sickle cell disease has included 6 dosed participants, including 4 from the last update in June. The data presented at ASH included 3 patients who had reached the three-month follow-up mark.

All 3 patients reported no VOC events in a follow-up range of 3-15 months after CTX001 infusion. Patient hemoglobin levels ranged from 11.5-13.2 g/dL, and HbF ranged from 31.3-48.0%.

In safety outcomes, investigators reported no serious adverse events, and consistent tolerability of therapy.

Looking Ahead

Trial investigators and therapy developers expressed shared measured adulation for the preliminary data which makes CTX001 the furthest-progressed gene-editing therapy in assessment for both patients with TDT and sickle cell disease.

As Haydar Frangoul, MD, Medical Director of Pediatric Hematology and Oncology at the Sarah Cannon Research Institute said in a statement, the vision of providing transformative care via stem cell transplant was unimaginable only a few years ago.

With these data in 10 patients, we can see the potential to fulfill this vision, Frangoul said. With more data and longer duration of follow-up, we will hopefully confirm that we have a durable therapy that may transform the lives of many patients.

As the first published results from a CRISPR/Cas9 therapy in patients with a genetic condition, the new ASH data represent what Reshma Kewalramani, MD, Vertex chief executive officer and president, called these findings an important milestone in medicine.

With clinical proof-of-concept for both beta thalassemia and sickle cell disease and 19 patients dosed, we look forward to continued efforts to bring our investigational treatment to patients living with TDT and SCD as quickly as we can, Kewalramani said.

Given the various designations granted by the FDA for the investigated use of CTX001, as well as these still developing, historic findings, optimism is high for a possibly marketed, disease-modifying gene-editing therapy for patients with TDT or sickle cell disease.

See the original post:
Gene-Editing Therapy CTX001 Reports Durable Effects for TDT, Sickle Cell Patients - MD Magazine

New Cedars-Sinai Biomanufacturing Center to Spur Cell Therapies – Newswise

Newswise LOS ANGELES (Dec. 4, 2020) -- Cedars-Sinai has launched a center to manufacture the next generation of stem cell and gene therapies that will enable biomedical researchers, government medical programs, commercial entities and others to develop new biologic drugs and propel novel disease discoveries.

Biologic drugs are produced from living organisms or contain components of living organisms, such as cells, proteins or genes.

"TheCedars-Sinai Biomanufacturing Centerleverages our world-class stem-cell expertise, which already serves scores of clients, to provide a much-needed biomanufacturing facility in Southern California," saidClive Svendsen, PhD, executive director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute. "It is revolutionary by virtue of elevating regenerative medicine and its therapeutic possibilities to an entirely new level-repairing the human body."

Among the facility's initial clients is the Department of Defense, which has asked Cedars-Sinai scientists to manufacture banks of stem cells from multiple healthy volunteers for later use in repairing vascular injuries sustained by military personnel in combat.

The core technology of the Cedars-Sinai Biomanufacturing Center involves production of specialized cells known as induced pluripotent stem cells, or iPSCs. Scientists make iPSCs by genetically converting adult blood cells into cells that can self-renew indefinitely and differentiate into nearly any type of tissue. Each resulting cell carries the exact DNA of the person who donated the blood sample.

"IPSCs are powerful tools for understanding human disease and developing therapies," saidDhruv Sareen, PhD, executive director of the Biomanufacturing Center and director of the induced pluripotent stem cell facility at the Regenerative Medicine Institute. "These cells enable us to truly practiceprecision medicineby developing drug treatments tailored to the individual patient or groups of patients with similar genetic profiles."

The Biomanufacturing Center is designed to address a critical bottleneck in bringing cell- and gene-based therapies to the clinic. It will help relieve a nationwide shortage of facilities that can scale up production of cells for drug products that consistently meet current good manufacturing practice (cGMP) standards for strength, quality, and purity. These standards, set by the U.S. Food and Drug Administration, must be met when producing pharmaceuticals for use in humans.

To comply with the federal standards, the new Cedars-Sinai center features nine "clean rooms" that maintain rigorously aseptic conditions for handling of all biomaterials. These rooms are supported by staging areas, gowning rooms, quality control laboratories and storage rooms with ample freezers and liquid nitrogen tanks.

Other sections of the Biomanufacturing Center are devoted to research and production of iPSC cells, technology and development, training and collaboration laboratories, offices, and facilities maintenance equipment. Overall, the center occupies more than 28,000 square feet.

"Our expansive facilities provide complete, end-to-end support of biomedical research and development of cell therapies that are 'living medicines,'" said Sareen, assistant professor of Biomedical Sciences. "We enable our clients to explore and create new types of cells, use them to make discoveries about diseases and transform the resulting biomaterials into cGMP-compliant therapies for testing in clinical trials."

The recent grand opening of the Biomanufacturing Center, hosted on a virtual platform by Cedars-Sinai leadership, was attended by representatives of local and federal governments, biotechnology companies, funding organizations and other stakeholders. It was followed by another Cedars-Sinai virtual event, a "Symposium on Translational Medicine and Biomanufacturing," that drew world-renowned keynote speakers from academia and industry and hundreds of attendees to explore the latest developments in these fields.

"Our new Biomanufacturing Center reaffirms Cedars-Sinai's commitment to deliver the finest clinical care for our patients-and patients everywhere-by expanding the frontiers of medical science," said Svendsen, professor of Biomedical Sciences and Medicine.

Read more on the Cedars-Sinai Blog:What Are Induced Pluripotent Stem Cells?

More:
New Cedars-Sinai Biomanufacturing Center to Spur Cell Therapies - Newswise

Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD). The data from this clinical trial could provide proof-of-concept for MGTA-145, in combination with plerixafor, as the preferred mobilization regimen for patients with SCD. bluebird bios experience with plerixafor as a mobilization agent in sickle cell disease aligns with Magentas combination therapy approach, utilizing MGTA-145 plus plerixafor with potential to achieve safe, rapid and reliable mobilization of sufficient quantities of high-quality stem cells to improve outcomes associated with stem cell transplantation. Under the collaboration, the stem cells will be fully characterized, and Magenta will undertake preclinical studies to evaluate the ability of these cells to be gene corrected and engrafted in mouse models. The companies will co-fund the clinical trial and Magenta will retain all rights to its product candidate.

We are excited to build upon our leading position in the field of ex-vivo gene therapy and the promising clinical data with LentiGlobin in SCD with a collaboration focused on achieving improved stem cell mobilization, said Dave Davidson, M.D., chief medical officer, bluebird bio. In this initial study, we hope to establish whether the combination of plerixafor with MGTA-145 can generate appropriate CD34+ stem cells with a single round of mobilization. If successful, we hope to evaluate this novel mobilization regimen with LentiGlobin to make another step forward in the treatment of patients with SCD.

Achieving reliable and rapid stem cell mobilization and a simplified collection process can ensure the entire patient experience is optimal with respect to therapeutic outcome. The incorporation of bluebird bios experience in this area of treatment will be immensely valuable in further developing MGTA-145 plus plerixafor to address the remaining unmet needs in gene therapy approaches for diseases like sickle cell disease, said John Davis Jr., M.D., M.P.H., M.S., Head of Research & Development and Chief Medical Officer, Magenta Therapeutics. We look forward to collaborating with bluebird bio to evaluate MGTA-145 as the preferred mobilization option for people with sickle cell disease.

SCD is a serious, progressive and debilitating genetic disease caused by a mutation in the -globin gene that leads to the production of abnormal sickle hemoglobin (HbS), causing red blood cells (RBCs) to become sickled and fragile, resulting in chronic hemolytic anemia, vasculopathy and painful vaso-occlusive events (VOEs). For adults and children living with SCD, this means unpredictable episodes of excruciating pain due to vaso-occlusion as well as other acute complicationssuch as acute chest syndrome (ACS), stroke, and infections, which can contribute to early mortality in these patients.

Currently available mobilization drugs, including granulocyte-colony stimulating factor (G-CSF), a commonly used mobilization agent administered over the course of five to seven days in other transplant settings, is not used in sickle cell disease because it can trigger vaso-occlusive crises and even death in adults and adolescents. Plerixafor is used to mobilize a patients stem cells for collection prior to transplant and while an available treatment option, multiple cycles of apheresis and collection may sometimes be required to generate sufficient stem cells for gene therapy. Magenta is developing MGTA-145, in combination with plerixafor, to be the preferred mobilization regimen for rapid and reliable mobilization and collection of hematopoietic stem cells (HSCs) to improve stem cell transplantation outcomes in multiple disease areas, including genetic diseases such as sickle cell disease, as well as blood cancers and autoimmune diseases.

About Magenta Therapeutics MGTA-145

MGTA-145, in combination with plerixafor, has demonstrated, in a recently completed Phase 1 study in healthy volunteers, it can rapidly and reliably mobilize high numbers of functional stem cells in a single day, without the need for G-CSF. MGTA-145 works in combination with plerixafor to harness a physiological mechanism of stem cell mobilization to rapidly and reliably mobilize HSCs for collection and transplant across multiple indications.

Additionally, as shown in preclinical studies, stem cells mobilized with MGTA-145 can be efficiently gene-modified and are able to engraft, potentially allowing for safer and more efficient mobilization for gene therapy approaches to treat sickle cell disease and other genetic diseases.

Magenta completed its Phase 1 trial of MGTA-145 in healthy volunteers, demonstrating MGTA-145 was well tolerated and enables same-day dosing, mobilization and simplified collection of sufficient stem cells for transplant, meeting all primary and secondary endpoints.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, were developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, were working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. Were putting our care and expertise to work across a spectrum of disorders: cerebral adrenoleukodystrophy, sickle cell disease, -thalassemia and multiple myeloma, using gene and cell therapy technologies including gene addition, and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

LentiGlobin and bluebird bio are trademarks of bluebird bio, Inc.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as may, will, could, should, expects, intends, plans, anticipates, believes, estimates, predicts, projects, seeks, endeavour, potential, continue or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption Risk Factors in Magentas Annual Report on Form 10-K filed on March 3, 2020, and in bluebird bios Annual Report on Form 10-K filed on February 18, 2020, as updated by each companys most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta and bluebird bio believe that the expectations reflected in the forward-looking statements are reasonable, neither Magenta nor bluebird bio can guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta or bluebird bio, nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. Neither Magenta nor bluebird undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Continue reading here:
Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta's MGTA-145 for Mobilizing and Collecting...

Global Single-cell Analysis Market Research Report 2020-2026 Featuring Major Players and Companies to Watch in the Future – PRNewswire

DUBLIN, Dec. 1, 2020 /PRNewswire/ -- The "Single-cell Analysis Market by Product, Cell Type, Technique, End User, and by Geography - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Single-cell Analysis Market is predicted to grow at a CAGR of ~17.1%. The market is predicted to reach $2005 million in 2026 from $763.4 million in 2020.

The information collected from this analysis is significant for cancer research for the discovery of tumor cells and genetic diagnosis. The factors such as advanced technology in products of single-cell analysis, increasing preference for customized medicine and rapidly increasing various chronic diseases such as cancer, which fuel the demand for the single-cell analysis market. However, the expensive products in the single-cell analysis are restraining market growth.

Single-cell analysis is the examination & study of proteins, study of small molecules, and other cells at the single-cell level. This analysis allows the study of variations of cell-to-cell in the group of cells. The objective of the single-cell analysis is to gain insight into the mechanisms of cellular functionality, which requires an understanding of each of the cellular components, including protein content, DNA, and RNA, as well as the cellular metabolites.

In the product based segmentation consumables segment is expected to have the largest share in the market. The reasons for the demand for consumables products are regularly purchasing the consumables compared to the instruments and the significant usage of consumables in the research and genetic exploration and segregation of RNA and DNA.

Based on cell type segmentation, the human cell segment is having the largest share in the market. The human cell is greatly used in the research laboratories due to the rising incidence of infectious diseases in the elderly population and the high investments in stem cell research.

On the bases of technique, the next-generation sequencing segment is expected to have the largest share in the market due to the increasing chronic diseases and next-generation sequencing allowing researchers to perform various applications.

Further, based on end-user segmentation, the academic and research laboratories segment is expected to have the largest share in the market. The increasing number of colleges and universities of medical and high investments in life science research are the factors accelerating the demand for single-cell analysis.

Moreover, based on the geography Asia Pacific region is playing a vital role in the market share compared to other regions due to rising number of patients in countries such as China and India, growing investments in the research and development in this field and outsourcing of drug discovery services to the Asia Pacific region. In addition, North America is the second-largest contributor to the market due to the high expenditure in the research and development and increased scope for stem cell research in this region.

The single-cell analysis market is expanding globally due to the increasingly advanced technology in the single-cell analysis products. The major factors accelerating the single-cell analysis market include rapidly increasing chronic diseases and cancer cases all over the world, increasing biotechnology & biopharmaceutical industries, and life science research. Although, due to high competition, the persistence of new entrants and small players is difficult in the market, and this is a challenge for market growth. The emerging markets in Asia are the future opportunities for the market.

The key market competitors in the market are Becton, Dickinson and Company, Danaher Corporatio, Merck Millipore, Qiagen N.V., Thermo Fisher Scientific, Inc, General Electric Company, BARCO, Promega Corporation, Shanghai Goodview Electronics, Fluidigm Corporation, Agilent Technologies, Inc, Nanostring Technologies, Inc., Tecan Group Ltd, Sartorius AG, LUMINEX CORPORATION, Takara Bio Inc., Takara Bio Inc., Fluxion Biosciences and Menarini Silicon Biosystems.

Moreover, the single-cell analysis has the largest scope in cancer research for the detection of the various tumor cells, preimplantation, and genetic diagnosis as the drastic increase in the cancer cases globally. The government is also supporting financially for cell-based research.

Key Topics Covered:

1. Executive Summary

2. Industry Outlook

3. Market Snapshot

3.1. Market Definition

3.2. Market Outlook

3.3. PEST Analysis

3.4. Porter Five Forces

3.5. Related Markets

4. Market characteristics

4.1. Market Evolution

4.2. Market Trends and Impact

4.3. Advantages/Disadvantages of Market

4.4. Regulatory Impact

4.5. Market Offerings

4.6. Market Segmentation

4.7. Market Dynamics

4.8. DRO - Impact Analysis

5. Technique: Market Size & Analysis

5.1. Overview

5.2. Consumables

5.2.1. Beads

5.2.2. Microplates

5.2.3. Reagents

5.2.4. Assay Kits

5.2.5. Other Consumables

5.3. Instruments

5.3.1. Flow Cytometers

5.3.2. NGS Systems

5.3.3. PCR Instruments

5.3.4. Spectrophotometers

5.3.5. Microscopes

5.3.6. Cell Counters

5.3.7. HCS Systems

5.3.8. Microarrays

5.3.9. Other Instruments

6. Cell Type: Market Size & Analysis

6.1. Overview

6.2. Human Cells

6.3. Animal Cells

6.4. Microbial Cells

7. Technique: Market Size & Analysis

7.1. Overview

7.2. Flow Cytometry

7.3. Next-generation Sequencing

7.4. Polymerase Chain Reaction

7.5. Microscopy

7.6. Mass Spectrometry

7.7. Other Techniques

8. End User: Market Size & Analysis

8.1. Overview

8.2. Academic & Research Laboratories

8.3. Biotechnology & Pharmaceutical Companies

8.4. Hospitals & Diagnostic Laboratories

8.5. Cell Banks & IVF Centers

9. Geography: Market Size & Analysis

9.1. Overview

9.2. North America

9.3. Europe

9.4. Asia Pacific

9.5. Rest of the World

10. Competitive Landscape

10.1. Competitor Comparison Analysis

10.2. Market Developments

10.3. Mergers and Acquisitions, Legal, Awards, Partnerships

10.4. Product Launches and execution

11. Vendor Profiles

11.1. Becton, Dickinson and Company

11.2. Danaher Corporation

11.3. Merck Millipore.

11.4. Qiagen N.V.

11.5. Thermo Fisher Scientific, Inc

11.6. General Electric Company

11.7. BARCO

11.8. Promega Corporation

11.9. Shanghai Goodview Electronics

12. Companies to Watch

12.1. Fluidigm Corporation

12.2. Agilent Technologies, Inc

12.3. Nanostring Technologies, Inc.

12.4. Tecan Group Ltd

12.5. Sartorius AG

12.6. LUMINEX CORPORATION

12.7. Takara Bio Inc.

12.8. Fluxion Biosciences

12.9. Menarini Silicon Biosystems

Companies Mentioned

Becton

Continued here:
Global Single-cell Analysis Market Research Report 2020-2026 Featuring Major Players and Companies to Watch in the Future - PRNewswire